Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2018-12-19 Capital/Financing Update
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges announcing the release of General Claims Escrow related to a past transaction (sale of Agila Specialties). It mentions a financial amount (~US$ 42 Mn) being received immediately due to resolution of claims and arbitration. The document is short (1792 characters) and serves as an announcement of a financial update related to a past transaction, not a full financial report or earnings release. It does not contain detailed financial statements or comprehensive financial results. It is an update on a capital-related event (release of escrow funds from a sale transaction). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-12-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for Lidocaine Ointment. It contains no financial statements, detailed financial analysis, or regulatory filings. The document is short (3716 characters) and serves as a public announcement of a product approval event. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a corporate announcement about a product approval, which is best classified as a general regulatory announcement or miscellaneous filing. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS).
2018-12-12 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing that Strides Vivimed JV has received US FDA approval for Albendazole Tablets. It is a short communication focused on a regulatory approval event and product launch, not a financial report or detailed investor presentation. It does not contain financial statements, management discussion, or detailed corporate governance information. It is not an announcement of voting results, nor a regulatory filing in the sense of compliance documents. The document is a typical press release about a product approval, which fits best under the category of Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product portfolio and market potential. The document length is 3445 characters, which is short and consistent with a press release rather than a full report. Therefore, the most appropriate classification is CAP with high confidence.
2018-12-11 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated November 22, 2018, from Strides Pharma Science Limited announcing an update on their investment in Stelis Biopharma. It details the company's participation in a Series B funding round, ownership percentages, and updates on Stelis' manufacturing facility and product pipeline. The document is a communication to stock exchanges (BSE and NSE) and is titled as a 'Press Release'. It does not contain financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. It is an announcement about capital investment and fundraising activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 5983 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2018-11-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic partnership between Strides Pharma Science Limited and SUDA Pharmaceuticals for the US market. It details the terms of the agreement, product information, and company background. There is no financial data, regulatory filing, or report attached or referenced as being published. The content is a corporate announcement about a business development and partnership, not a financial report, regulatory filing, or management update. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate communication, which corresponds to Regulatory Filings (RNS).
2018-11-09 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a US FDA inspection at the company's flagship facility. It is a short communication primarily providing an update on regulatory inspection status (Zero 483 observations). It does not contain financial statements, detailed financial performance, or management discussion. It is not an earnings release or a detailed investor presentation. The document is a public announcement of a regulatory event related to the company, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2018-11-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.